Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
Mosqueda-Gómez JL, Montaño-Loza A, Rolón AL, Cervantes C, Bobadilla-del-Valle JM, Silva-Sánchez J, Garza-Ramos U, Villasís-Keever A, Galindo-Fraga A, Palacios GM, Ponce-de-León A, Sifuentes-Osornio J. Mosqueda-Gómez JL, et al. Int J Infect Dis. 2008 Nov;12(6):653-9. doi: 10.1016/j.ijid.2008.03.008. Epub 2008 Jun 3. Int J Infect Dis. 2008. PMID: 18511321 Free article.
Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.
Belaunzarán-Zamudio PF, García-León ML, Wong-Chew RM, Villasís-Keever A, Cuellar-Rodríguez J, Mosqueda-Gómez JL, Muñoz-Trejo T, Escobedo K, Santos JI, Ruiz-Palacios GM, Sierra-Madero JG. Belaunzarán-Zamudio PF, et al. Vaccine. 2009 Nov 23;27(50):7059-64. doi: 10.1016/j.vaccine.2009.09.063. Epub 2009 Sep 30. Vaccine. 2009. PMID: 19799846
[Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A, Villasis-Keever A, Hernández-Bribiesca ME, Crespo-Solis E, Ruiz-Palacios GM, Sifuentes-Osornio J, Ponce-De-León-Garduño A. Ugarte-Torres A, et al. Rev Invest Clin. 2006 Nov-Dec;58(6):547-54. Rev Invest Clin. 2006. PMID: 17432285 Spanish.
Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, Juárez-Kasusky I, Magana-Aquino M, Ramos-Santos C, Pérez-Saleme L, Rangel-Frausto S, Antuna-Puente B, Soto-Ramírez LE, Lima V, Belaunzarán-Zamudio F, Crabtree-Ramírez B, Montaner J. Sierra-Madero J, et al. J Acquir Immune Defic Syndr. 2010 Apr;53(5):582-8. doi: 10.1097/QAI.0b013e3181cae4a1. J Acquir Immune Defic Syndr. 2010. PMID: 20090545 Clinical Trial.
[Infections in bone marrow transplantation].
Villasís-Keever A, Mosqueda JL. Villasís-Keever A, et al. Rev Invest Clin. 2005 Mar-Apr;57(2):381-6. Rev Invest Clin. 2005. PMID: 16524081 Review. Spanish. No abstract available.
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team. Ofotokun I, et al. Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12. Clin Infect Dis. 2015. PMID: 25767256 Free PMC article. Clinical Trial.
27 results